Projects

RNDr. Ján Sedlák, DrSc.
senior scientist

International

Finished
  • Arsenic in cancer treatment: mechanism of action and new forms of delivery
    Program: Inter-academic agreement
    Duration: 1. 1. 2011 – 31. 12. 2013

National

Finished
  • Harnessing the immunological mechanisms in various subtypes of B cell lymphoma
    Program: SRDA
    Duration: 1. 7. 2020 – 30. 6. 2024
  • Anti-myeloma activity by composite realgar nanomaterials and its mechanism in vitro and in vivo
    Program: VEGA
    Duration: 1. 1. 2020 – 31. 12. 2022
  • Development of novel diagnostic and predictive high-dimensional immunophenotyping tool for hematological malignancies
    Program: Other projects
    Duration: 1. 11. 2019 – 31. 12. 2022
  • Assessment of immune checkpoints in B cell malignancies
    Program: VEGA
    Duration: 1. 1. 2020 – 31. 12. 2022
  • Diagnostic potential of body fluid fluorescent characteristics and extracellular microvesicles analyses in urogenital malignancies
    Program: VEGA
    Duration: 1. 1. 2018 – 31. 12. 2021
  • The application of myrosinase for sulforaphane activation in development of a novel product exhibiting cancer prevention effects
    Program: SRDA
    Duration: 1. 7. 2017 – 31. 12. 2021
  • Prognostic biomarker for colorectal carcinoma based on miRNA analysis and characterization of selected proteins in the circadian context
    Program: SRDA
    Duration: 1. 7. 2015 – 30. 6. 2019
  • The biological effects of the environment with reduced deuterium (D) content or increased pH and physical exercise in relation to cancer: implications for tertiary prevention.
    Program: VEGA
    Duration: 1. 1. 2016 – 31. 12. 2018
  • The role of exosomes in the process of chemoresistence of ovarian carcinoma
    Program: VEGA
    Duration: 1. 1. 2016 – 31. 12. 2018
  • Role of microenvironment and B-cell immunity in the spontaneous regression of MM patients undergoing hight dose therapy and autologous stem cell transplantation
    Program: SRDA
    Duration: 1. 10. 2013 – 30. 6. 2017
  • Study of exosome production and the impact of chemotherapeutics on their properties
    Program: VEGA
    Duration: 1. 1. 2013 – 31. 12. 2016
  • -
    Program: EU Structural Funds Research & Development
    Duration: 1. 3. 2013 – 31. 7. 2015
  • Center of excellence for the study of metabolic aspects of development, diagnostics and treatment of cancer diseases
    Program:
    Duration: 1. 7. 2011 – 31. 12. 2014
  • -
    Program:
    Duration: 1. 6. 2011 – 31. 12. 2014
  • Anticancer effects of isothiocyanates and their combination with other therapeutic approaches.
    Program: VEGA
    Duration: 1. 1. 2011 – 31. 12. 2014
  • -
    Program: EU Structural Funds Research & Development
    Duration: 1. 6. 2011 – 30. 9. 2014
  • Implementation of radiobiological research of intensity-modulated proton therapy into clinical oncology practice
    Program: EU Structural Funds Research & Development
    Duration: 20. 10. 2010 – 31. 3. 2014
  • Centre of Excellence on Translational Research in Molecular Medicine
    Program: EU Structural Funds Research & Development
    Duration: 1. 1. 2010 – 31. 12. 2012
  • Epigenetic inactivation of selected genes for growth, invazivity and metastasis regulation in breast cancers
    Program: VEGA
    Duration: 1. 1. 2010 – 31. 12. 2012
  • Cisplatin resistance in human ovarian cancer cells and its modulation by signaling pathway- and nuclear transcription factor NF kappa-B inhibition
    Program: VEGA
    Duration: 1. 1. 2010 – 31. 12. 2012
  • Centre of Excellence for Translational Research in Molecular medicine
    Program: EU Structural Funds Research & Development
    Duration: 1. 6. 2010 – 31. 5. 2012
  • Centre for Signalosome Research
    Program: SRDA
    Duration: 1. 7. 2008 – 30. 6. 2011
  • Center of Excelence for Translational Research in Molecular Medicine
    Program: EU Structural Funds Research & Development
    Duration: 1. 6. 2009 – 31. 5. 2011
  • -
    Program: EU Structural Funds Research & Development
    Duration: 20. 5. 2009 – 19. 5. 2011
  • The role of genetic, epigenetic and phenotypic markers of the MDR1 gene and protein for the prognosis and treatment of the acute myeloid leukemia
    Program: VEGA
    Duration: 1. 1. 2008 – 31. 12. 2010
  • Effect of natural compounds isothiocyanates (ITCs) on cellular mechanisms and markers associated with aggressive phenotype and treatment responsiveness in breast and ovarian cancer
    Program: VEGA
    Duration: 1. 1. 2008 – 31. 12. 2010
  • Cytogenetic monitoring of the responses of the patients with carcinoma theradiotherapy succes
    Program: VEGA
    Duration: 1. 1. 2007 – 31. 12. 2009
  • Chemotherapy, multidrug resistance (MDR) its modulation and relationship of these events to programmed cell death (apoptosis) in human tumor cells
    Program: VEGA
    Duration: 1. 1. 2007 – 31. 12. 2009
  • Epithelial-mesenchymal transition in the model of breast carcinoma stem cells in vitro
    Program: SRDA
    Duration: 1. 3. 2006 – 1. 3. 2009
  • Monitoring of immunological parameters of multiple myeloma patients during course of Biobran consumption
    Program: Other projects
    Duration: 1. 1. 2005 – 31. 12. 2008
  • Study of new prognostic markers of therapeutical approaches in gynecologic malignancies: factors and pathways influencing course of the disease and antitumour immunity
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
Employees